These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 26671484)
21. NK cell frequency and cytotoxicity in correlation to pregnancy outcome and response to IVIG therapy among women with recurrent pregnancy loss. Ahmadi M; Ghaebi M; Abdolmohammadi-Vahid S; Abbaspour-Aghdam S; Hamdi K; Abdollahi-Fard S; Danaii S; Mosapour P; Koushaeian L; Dolati S; Rikhtegar R; Oskouei FD; Aghebati-Maleki L; Nouri M; Yousefi M J Cell Physiol; 2019 Jun; 234(6):9428-9437. PubMed ID: 30317625 [TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulin therapy for recurrent spontaneous abortion: a meta-analysis. Daya S; Gunby J; Clark DA Am J Reprod Immunol; 1998 Feb; 39(2):69-76. PubMed ID: 9506204 [TBL] [Abstract][Full Text] [Related]
23. High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins. Perricone R; Di Muzio G; Perricone C; Giacomelli R; De Nardo D; Fontana L; De Carolis C Am J Reprod Immunol; 2006 Mar; 55(3):232-9. PubMed ID: 16451358 [TBL] [Abstract][Full Text] [Related]
24. Natural killer cell activity and cytokine production after in vitro immunoglobulin treatment of lymphocytes derived from pregnant women with or without risk for spontaneous abortion. Szereday L; Späth P; Szekeres-Bartho J Am J Reprod Immunol; 1999 Nov; 42(5):282-7. PubMed ID: 10584982 [TBL] [Abstract][Full Text] [Related]
25. Intralipid therapy and adverse reproductive outcome: is there any evidence? Kumar P; Marron K; Harrity C Reprod Fertil; 2021 Jul; 2(3):173-186. PubMed ID: 35118388 [TBL] [Abstract][Full Text] [Related]
26. Intralipid as treatment for recurrent unexplained abortion? Clark DA Am J Reprod Immunol; 1994 Dec; 32(4):290-3. PubMed ID: 7718096 [TBL] [Abstract][Full Text] [Related]
27. Effects of intralipid infusions on anti-trophoblast antibody (ATAb)-activities in patients with recurrent pregnancy loss: An observational report. Rogenhofer N; Mahner S; von Hasselbach YL; Thaler CJ Am J Reprod Immunol; 2022 Feb; 87(2):e13506. PubMed ID: 34935238 [TBL] [Abstract][Full Text] [Related]
28. Duration of intralipid's suppressive effect on NK cell's functional activity. Roussev RG; Acacio B; Ng SC; Coulam CB Am J Reprod Immunol; 2008 Sep; 60(3):258-63. PubMed ID: 18782287 [TBL] [Abstract][Full Text] [Related]
29. Intravenous immunoglobulin in the prevention of recurrent spontaneous abortion: the European experience. Christiansen OB Am J Reprod Immunol; 1998 Feb; 39(2):77-81. PubMed ID: 9506205 [TBL] [Abstract][Full Text] [Related]
30. Experience in IVIg therapy for selected women with recurrent reproductive failure and NK cell expansion. Ramos-Medina R; García-Segovia A; Gil J; Carbone J; Aguarón de la Cruz A; Seyfferth A; Alonso B; Alonso J; León JA; Alecsandru D; Meliá E; Carrillo de Albornoz E; Ordoñez D; Santillán I; Verdú V; Garcia Ruiz de Morales JM; López-Hoyos M; López Larios A; Sampalo A; Caballero P; Ortiz Quintana L; Fernández-Cruz E; Sánchez-Ramón S Am J Reprod Immunol; 2014 May; 71(5):458-66. PubMed ID: 24612159 [TBL] [Abstract][Full Text] [Related]
31. Bu-Shen-Yi-Qi formula impairs cytotoxicity of NK cells by up-regulating IDO expression in trophoblasts. Yang SL; Niu TT; Li XL; Li DJ; Li MQ; Wang HY Gynecol Endocrinol; 2018 Aug; 34(8):675-679. PubMed ID: 29334801 [TBL] [Abstract][Full Text] [Related]
32. Intralipid® may represent a new hope for patients with reproductive failures and simultaneously an over-immune endometrial activation. Lédée N; Vasseur C; Petitbarat M; Chevrier L; Vezmar K; Dray G; Chenière S; Lobersztajn A; Vitoux D; Cassuto GN; Chaouat G J Reprod Immunol; 2018 Nov; 130():18-22. PubMed ID: 30286362 [TBL] [Abstract][Full Text] [Related]
33. Intralipid therapy for unexplained recurrent miscarriage and implantation failure: Case-series and literature review. Plaçais L; Kolanska K; Kraiem YB; Cohen J; Suner L; Bornes M; Sedille L; Rosefort A; D'Argent EM; Selleret L; Abisror N; Johanet C; Buffet NC; Darai E; Antoine JM; Fain O; Kayem G; Mekinian A Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():100-104. PubMed ID: 32592916 [TBL] [Abstract][Full Text] [Related]
34. Declined Natural Killer Cells Emerging in Women with Unexplained Recurrent Spontaneous Abortion and Further Reducing after Medical Therapy. Lin X; Lin D; Liu J; Bao Y; Luo Z; Fang J; Wang Y; Zhao M; Duan C Clin Lab; 2016 Nov; 62(11):2241-2247. PubMed ID: 28164685 [TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin for treatment of recurrent pregnancy loss. Coulam CB; Krysa L; Stern JJ; Bustillo M Am J Reprod Immunol; 1995 Dec; 34(6):333-7. PubMed ID: 8607936 [TBL] [Abstract][Full Text] [Related]
37. Clinical Research into Treating Unexplained Recurrent Spontaneous Abortion during Early Pregnancy with the Qing Yi Tiao Mian Formula. Shen MJ; Pan DC; Du L; Jiang GJ Explore (NY); 2023; 19(1):52-57. PubMed ID: 35397998 [TBL] [Abstract][Full Text] [Related]
38. Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study. Jablonowska B; Selbing A; Palfi M; Ernerudh J; Kjellberg S; Lindton B Hum Reprod; 1999 Mar; 14(3):838-41. PubMed ID: 10221723 [TBL] [Abstract][Full Text] [Related]
39. Effects of polyvalent immunoglobulins in patients with recurrent pregnancy loss and antibodies to the choriocarcinoma cell line JEG-3. Rogenhofer N; von Schönfeldt V; Ochsenkühn R; Sili F; Thaler CJ Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():161-7. PubMed ID: 26407335 [TBL] [Abstract][Full Text] [Related]
40. Blocking antibodies in blood from patients with recurrent spontaneous abortion in relation to pregnancy outcome and intravenous immunoglobulin treatment. Jablonowska B; Palfi M; Ernerudh J; Kjellberg S; Selbing A Am J Reprod Immunol; 2001 Apr; 45(4):226-31. PubMed ID: 11327549 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]